Skip to main content
main-content

Connective tissue diseases

Clinical trials

Emerging therapies for lupus nephritis

Lupus nephritis is the most common organ-threatening complication of systemic lupus erythematosus, and current treatment regimens are only partially effective and are potentially toxic. In this editorial, the authors focus on emerging therapeutics to treat this disease.

29-01-2019 | Lupus nephritis | Editorial | Article

Emerging therapies for lupus nephritis

Lupus nephritis is the most common organ-threatening complication of systemic lupus erythematosus, and current treatment regimens are only partially effective and are potentially toxic. In this editorial, the authors focus on emerging therapeutics to treat this disease.

26-07-2018 | Scleroderma | Article

Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: Open label, randomized, controlled trial

Sircar G et al. Rheumatology (Oxford) 2018: key213. doi: 10.1093/rheumatology/key213

15-06-2018 | Systemic lupus erythematosus | EULAR 2018 | Video

Expert commentary: Promising results with herpes zoster vaccine in SLE patients

Thomas Dörner comments on study results demonstrating that a live attenuated herpes zoster vaccine is well tolerated and provokes an antibody response in patients with SLE (5:14).

Read the accompanying news story here

12-05-2018 | Systemic lupus erythematosus | Article

Nutritional intervention in patients with juvenile systemic lupus erythematosus: Protective effect against the increase in fat mass

Abad TO et al. Rheumatol Int 2018; Advance online publication. doi: 10.1007/s00296-018-4031-3

New trials in lupus and where are we going

In this article, the authors review progress in the field of clinical trials for systemic lupus erythematosus [read more].
Thanou A, Merrill JT. Curr Rheumatol Rep 2018; 20: 34. doi: 10.1007/s11926-018-0745-1

03-05-2018 | Systemic lupus erythematosus | Review | Article

New trials in lupus and where are we going

In this article, the authors review progress in the field of clinical trials for systemic lupus erythematosus.

Thanou A, Merrill JT. Curr Rheumatol Rep 2018; 20: 34. doi: 10.1007/s11926-018-0745-1

24-01-2018 | Pathogenesis | Review | Article

Moving towards a molecular taxonomy of autoimmune rheumatic diseases

Barturen G et al. Nat Rev Rheumatol 2018; 14: 75–93. doi: 10.1038/nrrheum.2017.220

09-03-2017 | Systemic lupus erythematosus | Article

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study

The OBSErve Canada Study results, reported here, deliver insights into the overall pattern of systemic lupus erythematosus care, characteristics of patients receiving belimumab, and clinical outcomes following treatment.

Touma Z et al. Rheumatol Int 2017;37:865–873. doi:10.1007/s00296-017-3682-9

image credits